L Desdentado1, R Espert1,2, P Sanz3, J Tirapu-Ustarroz4. 1. Hospital Clinico Universitario de Valencia, 46010 Valencia, Espana. 2. Universidad de Valencia, 46071 Valencia, Espana. 3. Instituto de Biomedicina de Valencia, 46010 Valencia, Venezuela. 4. Fundacion Argibide, Pamplona, Espana.
Abstract
INTRODUCTION: Lafora disease is autosomal recessive progressive myoclonus epilepsy with late childhood-to teenage-onset caused by loss-of-function mutations in either EPM2A or EPM2B genes encoding laforin or malin, respectively. DEVELOPMENT: The main symptoms of Lafora disease, which worsen progressively, are: myoclonus, occipital seizures, generalized tonic-clonic seizures, cognitive decline, neuropsychiatric syptoms and ataxia with a fatal outcome. Pathologically, Lafora disease is characterized by the presence of polyglucosans deposits (named Lafora bodies), in the brain, liver, muscle and sweat glands. Diagnosis of Lafora disease is made through clinical, electrophysiological, histological and genetic findings. Currently, there is no treatment to cure or prevent the development of the disease. Traditionally, antiepileptic drugs are used for the management of myoclonus and seizures. However, patients become drug-resistant after the initial stage. CONCLUSIONS: Lafora disease is a rare pathology that has serious consequences for patients and their caregivers despite its low prevalence. Therefore, continuing research in order to clarify the underlying mechanisms and hopefully developing new palliative and curative treatments for the disease is necessary.
INTRODUCTION:Lafora disease is autosomal recessive progressive myoclonus epilepsy with late childhood-to teenage-onset caused by loss-of-function mutations in either EPM2A or EPM2B genes encoding laforin or malin, respectively. DEVELOPMENT: The main symptoms of Lafora disease, which worsen progressively, are: myoclonus, occipital seizures, generalized tonic-clonic seizures, cognitive decline, neuropsychiatric syptoms and ataxia with a fatal outcome. Pathologically, Lafora disease is characterized by the presence of polyglucosans deposits (named Lafora bodies), in the brain, liver, muscle and sweat glands. Diagnosis of Lafora disease is made through clinical, electrophysiological, histological and genetic findings. Currently, there is no treatment to cure or prevent the development of the disease. Traditionally, antiepileptic drugs are used for the management of myoclonus and seizures. However, patients become drug-resistant after the initial stage. CONCLUSIONS:Lafora disease is a rare pathology that has serious consequences for patients and their caregivers despite its low prevalence. Therefore, continuing research in order to clarify the underlying mechanisms and hopefully developing new palliative and curative treatments for the disease is necessary.
Authors: D M Andrade; C A Ackerley; T S C Minett; H A G Teive; S Bohlega; S W Scherer; B A Minassian Journal: Neurology Date: 2003-12-09 Impact factor: 9.910
Authors: E M Chan; D E Bulman; A D Paterson; J Turnbull; E Andermann; F Andermann; G A Rouleau; A V Delgado-Escueta; S W Scherer; B A Minassian Journal: J Med Genet Date: 2003-09 Impact factor: 6.318
Authors: Hannes Lohi; Leonarda Ianzano; Xiao-Chu Zhao; Elayne M Chan; Julie Turnbull; Stephen W Scherer; Cameron A Ackerley; Berge A Minassian Journal: Hum Mol Genet Date: 2005-08-22 Impact factor: 6.150
Authors: C Gómez-Abad; P Gómez-Garre; E Gutiérrez-Delicado; S Saygi; R Michelucci; C A Tassinari; S Rodríguez de Córdoba; J M Serratosa Journal: Neurology Date: 2005-03-22 Impact factor: 9.910
Authors: Elayne M Chan; Edwin J Young; Leonarda Ianzano; Iulia Munteanu; Xiaochu Zhao; Constantine C Christopoulos; Giuliano Avanzini; Maurizio Elia; Cameron A Ackerley; Nebojsa J Jovic; Saeed Bohlega; Eva Andermann; Guy A Rouleau; Antonio V Delgado-Escueta; Berge A Minassian; Stephen W Scherer Journal: Nat Genet Date: 2003-09-07 Impact factor: 38.330